Loading clinical trials...
Loading clinical trials...
The goal of this study is to demonstrate a significant gain in sensitivity versus surgical curage (extended pelvic) for initial lymph node staging of late FDG-PET images (2.5 hours) versus standard im...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Hopital Foch
NCT06529822 · Muscle-Invasive Bladder Carcinoma, Gastroesophageal Adenocarcinoma, and more
NCT07217171 · Bladder Cancer, Squamous Cell Carcinoma of the Lung, and more
NCT06851663 · Solid Tumor, Solid Carcinoma, and more
NCT05951179 · Non-muscle Invasive Bladder Cancer
NCT06417190 · Muscle-Invasive Bladder Carcinoma, Tumor
Hopital Foch
Suresnes, Île-de-France Region
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions